| P50 | author | Hertzel C. Gerstein | Q41696958 |
| | Alison C Holloway | Q88451199 |
| P2093 | author name string | Bart P Hettinga | |
| P2860 | cites work | Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells | Q39895082 |
| | Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells | Q42490936 |
| | Rosiglitazone improves pancreatic mitochondrial function in an animal model of dysglycemia: role of the insulin-like growth factor axis | Q42853592 |
| | Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study | Q42982910 |
| | Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death | Q43596005 |
| | Biotransformation of insulin glargine after subcutaneous injection in healthy subjects | Q44379874 |
| | Specific and Combined Effects of Insulin and Glucose on Functional Pancreatic β-Cell Mass in Vivo in Adult Rats | Q44440569 |
| | Reduced β-cell mass and altered glucose sensing impair insulin-secretory function in βIRKO mice | Q44602874 |
| | Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress | Q44815359 |
| | Rosiglitazone prevents diabetes by increasing beta-cell mass in an animal model of type 2 diabetes characterized by reduced beta-cell mass at birth | Q46923573 |
| | Effect of chronic rosiglitazone, metformin and glyburide treatment on beta-cell mass, function and insulin sensitivity in mZDF rats | Q46923579 |
| | Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. | Q51561183 |
| | Fetal and neonatal nicotine exposure and postnatal glucose homeostasis: identifying critical windows of exposure. | Q51748986 |
| | Type 2 diabetes-a matter of beta-cell life and death? | Q53873519 |
| | Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. | Q53979441 |
| | Selective β-Cell Loss and α-Cell Expansion in Patients with Type 2 Diabetes Mellitus in Korea | Q57214866 |
| | Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin | Q22250892 |
| | Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes | Q29619192 |
| | Glycemic control promotes pancreatic beta-cell regeneration in streptozotocin-induced diabetic mice | Q33525549 |
| | In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites | Q33537987 |
| | The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes | Q34127704 |
| | Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program | Q34335544 |
| | The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes | Q35085591 |
| | Development of the endocrine pancreas | Q36253123 |
| | Growth factors and beta cell replication. | Q36259876 |
| | Regulation of pancreatic beta-cell mass | Q36267776 |
| | Animal models of type 2 diabetes with reduced pancreatic beta-cell mass | Q36298862 |
| | Intrinsic regulators of pancreatic beta-cell proliferation | Q36528824 |
| | On the role of IRS2 in the regulation of functional beta-cell mass | Q36576524 |
| P433 | issue | 1 | |
| P921 | main subject | metformin | Q19484 |
| | (RS)-rosiglitazone | Q424771 |
| | type 2 diabetes | Q3025883 |
| P304 | page(s) | 74-81 | |
| P577 | publication date | 2011-03-01 | |
| P1433 | published in | Journal of diabetes | Q27020371 |
| P1476 | title | Effect of combining rosiglitazone with either metformin or insulin on β-cell mass and function in an animal model of Type 2 diabetes characterized by reduced β-cell mass at birth | |
| P478 | volume | 3 | |